NICE's initial guidance on Breyanzi concluded it was not a cost-effective option for patients, but the agency said this ...

Galapagos shifts to CAR-T therapy with GLPG5101, targeting pivotal trials by 2026. Click here to find out why I rate GLPG ...

Bristol Myers Squibb & Co (NYSE:BMY) announced the final analysis of overall survival (OS) from the Phase 3 CheckMate -816 ...

A new treatment, lisocabtagene maraleucel, has been approved for NHS use, benefiting hundreds of blood cancer patients in England.

Final NICE guidance recommends lisocabtagene maraleucel (also called liso-cel or Breyanzi and made by Bristol Myers Squibb) as an option for treating people with large B-cell lymphoma ...

An innovative new treatment is set to benefit hundreds of people in England with aggressive blood cancer after it was given ...

Two months after Allogene abandoned plans for its CAR-T in leukemia, analysts have suggested that fresh phase 1 data in ...

During a Case-Based Roundtable® event, Nitin Jain, MD, and participants discussed treating a patient with CLL after ...

The drugmaker also won a CHMP endorsement for its CAR-T therapy Breyanzi to treat adults with relapsed or refractory follicular lymphoma (FL) who’ve previously tried two or more systemic therapies.

A third CD19-targeted CAR-T, Bristol-Myers Squibb's Breyanzi (lisocabtagene maraleucel), is on the market for other blood cancers, but not ALL. Aucatzyl will now have to carve out market share ...